| Description: |
Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders. |
| Target: |
IC50: 630 nM (Myeloperoxidase)[1] |
| In Vitro: |
Verdiperstat (AZD3241) is a myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and is used in the research of neurodegenerative brain disorders[1]. Verdiperstat (AZD3241) selectively and irreversibly inhibits myeloperoxidase, and may involves reduction of oxidative stress leading to reduction of sustained neuroinflammation[2]. |
| References: |
[1]. Johnström P, et al. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol. 2015 Jun;42(6):555-60.
[2]. Jucaite A, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. |
